References
- Wilke RA , LinDW, RodenDM et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Nat. Rev. Drug Discov.6 , 904–916 (2007).
- Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57 , 119–137 (2006).
- Sawyers CL : The cancer biomarker problem.Nature452 , 548–552 (2007).
- Ekhart C , RodenhuisS, SmitsPH, BeijnenJH, HuitemaAD: Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.Pharmacogenet. Genomics18 , 1009–1015 (2008).
- Spence JP , LiangT, ErikssonCJ et al.: Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations.Alcohol Clin. Exp. Res.27 , 1389–1394 (2003).
- Tsuchiya Y , NakajimaM, TakagiS et al.: MicroRNA regulates the expression of human cytochrome P450 1B1.Cancer Res.66 , 9090–9098 (2006).
References
- Monzo M , NavarroA, FerrerG, ArtellsR: Pharmacogenomics: a tool for improving cancer chemotherapy.Clin. Transl. Oncol.10 , 628–637 (2008).
- Tsuchiya N , InoueT, NaritaS et al.: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.J. Urol.180 , 2389–2395 (2008).
- Pirmohamed M , ParkBK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions.Toxicology192 , 23–32 (2003).
- Kiyotani K , MushirodaT, KuboM et al.: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.Cancer Sci.99 , 967–972 (2008).
References
- Yee HS , FongNT: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.Ann. Pharmacother.32 , 1030–1043 (1998).
- Noriega V , PennanenC, SanchezMP et al.: (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.Basic Clin. Pharmacol. Toxicol.104(3) , 211–215 (2008).
- Zuliani G , HobbsHH: A high frequency of length polymorphisms in repeated sequences adjacent to Alu sequences.Am. J. Hum. Genet.46 , 963–969 (1990).
- Hubacek JA , PistulkovaH, ValentaZ, PoledneR: (TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia.VASA28 , 169–171 (1999).
- Tong Y , ZhangS, LiH et al.: 8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease.Lipids39 , 239–241 (2004).
- Plat J , MensinkRP: Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption.Eur. J. Clin. Invest.32 , 242–250 (2002).
- Kathiresan S , WillerCJ, PelosoGM et al.: Common variants at 30 loci contribute to polygenic dyslipidemia.Nat. Genet.41 , 56–65 (2009).
- Chasman DI , PosadaD, SubrahmanyanL et al.: Pharmacogenetic study of statin therapy and cholesterol reduction.JAMA291 , 2821–2827 (2004).
- Krauss RM , MangraviteLM, SmithJD et al.: Variation in the 3-hydroxyl-3-methylglutaryl-coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.Circulation117 , 1537–1544 (2008).
- Thompson JF , ManM, JohnsonKJ et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response.Pharmacogenomics J.5 , 352–358 (2005).
- Medina MW , GaoF, RuanW et al.: Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.Circulation118 , 355–362 (2008).